Fundraising FoxExThera Medical
Martinez, US · Delaware corporation · 2 known investors
Find your way into ExThera Medical
Each arrow is one introduction. Sign up to fill in the first one.
273 people can intro you to Keith
Ask Steven P. LaRosa to introduce you to Keith McCrea
You →Steven · together at ExThera Medical →Keith
193 people can intro you to Michael
Ask Jamie Chen to introduce you to Michael DiMeo
You →Jamie · together at Exosome Diagnostics →Michael
60 people can intro you to Robert
Ask Sam Okafor to introduce you to Robert S. Ward
You →Sam · together at ExThera Medical →Robert
- Erin Borger1 person can intro you
Sign up to find every way you can get introduced to ExThera Medical
- Your email: who you already know at ExThera Medical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ExThera Medical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
MD
Michael DiMeoChief Financial OfficerMichael DiMeo is an executive with over 20 years of experience in strategic finance and operations within biotechnology and life sciences companies. He has led cross-functional teams across multiple countries and worked on commercial excellence, financial planning, and business transformation initiatives in diagnostics and innovation-driven environments.
EB
Erin BorgerCEO2023–2026Erin Borger previously served as Chief Executive of ExThera Medical, which develops extracorporeal blood filtration devices for removing pathogens from the bloodstream. He brings over 20 years of finance experience from roles at Morgan Stanley and UBS Financial Services, where he reached Managing Director and Market Head.
RS
Robert S. WardExecutiveRobert S. Ward is an executive officer and director at ExThera Medical. He has spent his career developing biomedical polymers for medical devices including cardiac assist systems, glucose sensors, orthopedic implants, and blood filters, and holds numerous patents in the field.
KM
Keith McCreaVice President of Research and Development, and Chief Science OfficerKeith McCrea holds a PhD in Physical Chemistry from UC Berkeley and has over 20 years of experience in medical device development, with expertise in materials science and polymer science. He is Chief Science Officer and VP of Research and Development at ExThera Medical and President of Stavro Medical.
Board
JP
John PrestonBoard director
JF
John FeikBoard director
JP
Jacqueline PriceBoard director
LC
Lakhmir ChawlaBoard director
EJ
Eber JaquesBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$62.8M disclosed across 6 rounds · 2012–2024
▶$1.5MraisedSep 2024 · 23 investors · Other Health CareRule 506(b)
▶$1.5MraisedSep 2024 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael DiMeoExecutive Officer
- Erin BorgerExecutive Officer, Director
- Jacqueline PriceDirector
- John PrestonDirector
- Robert S. WardExecutive Officer, Director
- Lakhmir ChawlaDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedSep 2021 · 12 investors · Other Health CareRule 506(b)
▶$6.7MraisedSep 2021 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert S. WardExecutive Officer, Director
- Lakhmir ChawlaDirector
- Michael BenjaminExecutive Officer
- Greg DollarhydeDirector
- Erin BorgerDirector
- John PrestonDirector
- Offering amount
- $20M
- Amount sold
- $6.7M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.6MraisedMar 2021 · 66 investors · Other Health CareRule 506(b)
▶$20.6MraisedMar 2021 · 66 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert S. WardExecutive Officer, Director
- John PrestonDirector
- Lakhmir ChawlaExecutive Officer, Director
- Michael PorterDirector
- Greg DollarhydeDirector
- Offering amount
- $20.6M
- Amount sold
- $20.6M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedMay 2016 · 29 investors · BiotechnologyRule 506(b)
▶$6.7MraisedMay 2016 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathleen WhiteExecutive Officer
- John FeikDirector
- George PitarraExecutive Officer, Director
- Eber JaquesDirector
- Robert WardExecutive Officer, Director
- Keith McCreaExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $6.7M
- Minimum investment
- $20K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.3MraisedMay 2016 · 30 investors · BiotechnologyRule 506(b)
▶$15.3MraisedMay 2016 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith McCreaExecutive Officer, Director
- Eber JaquesDirector
- George PitarraExecutive Officer, Director
- Robert WardExecutive Officer, Director
- Kathleen WhiteExecutive Officer
- John FeikDirector
- Offering amount
- $15.4M
- Amount sold
- $15.3M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMay 2016 · 20 investors · BiotechnologyRule 506(b)
▶$12MraisedMay 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith McCreaExecutive Officer, Director
- Kathleen WhiteExecutive Officer
- George PitarraExecutive Officer, Director
- Robert WardExecutive Officer, Director
- John FeikDirector
- Eber JaquesDirector
- Offering amount
- $12.5M
- Amount sold
- $12M
- First sale
- Apr 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
AltaThera PharmaceuticalsAltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
SonoTheraSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
RayTheraA biopharmaceutical company developing therapies for neurology, immunology, and rare diseases. The page describes work focused on treating hard-to-treat conditions.
CartheraCarthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.
Companies working in the same space as ExThera Medical.
In the news
Frequently asked questions
- Who are ExThera Medical's investors?
- ExThera Medical's investors include Cycad Group LLC, Fresenius Medical Care Ventures.
- How much funding has ExThera Medical raised?
- ExThera Medical has disclosed $62.8M raised across 6 rounds.
- Where is ExThera Medical headquartered?
- ExThera Medical is headquartered in Martinez, US.